Sign in

    Mike Ulz

    Research Analyst at Morgan Stanley

    Michael Ulz is an Executive Director of Biotechnology Equity Research at Morgan Stanley, focusing on the healthcare sector with specialization in biotechnology. He covers companies such as Sarepta Therapeutics, maintaining a consistent record of actionable recommendations, including a buy rating that produced a 451.7% return and a long-term average return around 37% across 74 stocks. Ulz began his career as a Vice President and analyst at Baird, where he covered biotechnology and healthcare stocks before joining Morgan Stanley in New York. He holds professional credentials with FINRA and is registered for securities licensing, gaining recognition through success rates exceeding 37% and making over 100 ratings during his tenure.

    Mike Ulz's questions to Y-mAbs Therapeutics (YMAB) leadership

    Mike Ulz's questions to Y-mAbs Therapeutics (YMAB) leadership • Q3 2024

    Question

    Representing Mike Ulz, Rohit asked for a breakdown of the Q3 DANYELZA sales decline, attributing it to seasonality, competition, and clinical trials, and requested more detail on the change in estimate for Medicaid claims.

    Answer

    Chief Financial Officer Pete Pfreundschuh clarified that the number of sites with higher Medicaid populations is increasing, leading to a $1.5 million downward adjustment in Q3. He also noted a $700,000 shipment timing issue that pushed sales into Q4. Chief Commercial Officer Sue Smith added that despite headwinds, key performance indicators like physician and patient starts are growing, particularly in high-volume centers, driven by a new competitive campaign focused on DANYELZA's value proposition.

    Ask Fintool Equity Research AI